biotech
biotech Articles
Dynavax Technologies saw its shares make a handy gain early on Wednesday after the company announced that it received a recommendation from the CDC's Advisory Committee on Immunization Practices.
Published:
Last Updated:
Tetraphase Pharmaceuticals saw its shares make a solid gain early on Wednesday after the company announced an exclusive licensing agreement in Asia.
Published:
Last Updated:
Aimmune Therapeutics shares initially made a handy gain on Tuesday after the company reported data from its late-stage peanut allergy trial.
Published:
Last Updated:
Here 24/7 Wall St. has included a calendar of a few of the biggest companies expecting clinical trial and FDA updates in February.
Published:
Last Updated:
Moleculin Biotech watched its shares climb on Thursday after the company announced a new breakthrough for cancer treatment.
Published:
Last Updated:
Tetraphase Pharmaceuticals saw its shares get cut in half on Wednesday after the firm provided an update on its late-stage clinical trial for the treatment of urinary tract infections.
Published:
Last Updated:
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
Published:
Last Updated:
Catabasis Pharmaceuticals saw its shares skyrocket on Tuesday after the firm announced new results from its Duchene muscular dystrophy study with edasalonexent.
Published:
Last Updated:
Clinical-stage biopharmaceutical company BioXel Therapeutics has filed with the SEC regarding its initial public offering.
Published:
Last Updated:
Axovant Sciences saw its shares take a big step back to start out the week after the company announced that there would be some changes at the executive level.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
Theravance Biopharma shares made a solid gain on Wednesday after the company announced a global collaboration with Janssen Biotech.
Published:
Last Updated:
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Published:
Last Updated:
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
Published:
Last Updated:
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
Published:
Last Updated: